Cargando…
Remote, proactive, telephone based management of toxicity in outpatients during adjuvant or neoadjuvant chemotherapy for early stage breast cancer: pragmatic, cluster randomised trial
OBJECTIVE: To evaluate the effectiveness of remote proactive management of toxicities during chemotherapy for early stage breast cancer. DESIGN: Pragmatic, cluster randomised trial. SETTING: 20 cancer centres in Ontario, Canada, allocated by covariate constrained randomisation to remote management o...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8652580/ https://www.ncbi.nlm.nih.gov/pubmed/34880055 http://dx.doi.org/10.1136/bmj-2021-066588 |
_version_ | 1784611599361769472 |
---|---|
author | Krzyzanowska, Monika K Julian, Jim A Gu, Chu-Shu Powis, Melanie Li, Qing Enright, Katherine Howell, Doris Earle, Craig C Gandhi, Sonal Rask, Sara Brezden-Masley, Christine Dent, Susan Hajra, Leena Freeman, Orit Spadafora, Silvana Hamm, Caroline Califaretti, Nadia Trudeau, Maureen Levine, Mark N Amir, Eitan Bordeleau, Louise Chiarotto, James A Elser, Christine Husain, Juhi Laferriere, Nicole Rahim, Yasmin Robinson, Andrew G Vandenberg, Ted Grunfeld, Eva |
author_facet | Krzyzanowska, Monika K Julian, Jim A Gu, Chu-Shu Powis, Melanie Li, Qing Enright, Katherine Howell, Doris Earle, Craig C Gandhi, Sonal Rask, Sara Brezden-Masley, Christine Dent, Susan Hajra, Leena Freeman, Orit Spadafora, Silvana Hamm, Caroline Califaretti, Nadia Trudeau, Maureen Levine, Mark N Amir, Eitan Bordeleau, Louise Chiarotto, James A Elser, Christine Husain, Juhi Laferriere, Nicole Rahim, Yasmin Robinson, Andrew G Vandenberg, Ted Grunfeld, Eva |
author_sort | Krzyzanowska, Monika K |
collection | PubMed |
description | OBJECTIVE: To evaluate the effectiveness of remote proactive management of toxicities during chemotherapy for early stage breast cancer. DESIGN: Pragmatic, cluster randomised trial. SETTING: 20 cancer centres in Ontario, Canada, allocated by covariate constrained randomisation to remote management of toxicities or routine care. PARTICIPANTS: All patients starting adjuvant or neoadjuvant chemotherapy for early stage breast cancer at each centre. 25 patients from each centre completed patient reported outcome questionnaires. INTERVENTIONS: Proactive, standardised, nurse led telephone management of common toxicities at two time points after each chemotherapy cycle. MAIN OUTCOME MEASURES: The primary outcome, cluster level mean number of visits to the emergency department or admissions to hospital per patient during the whole course of chemotherapy treatment, was evaluated with routinely available administrative healthcare data. Secondary patient reported outcomes included toxicity, self-efficacy, and quality of life. RESULTS: Baseline characteristics of participants were similar in the intervention (n=944) and control arms (n=1214); 22% were older than 65 years. Penetration (that is, the percentage of patients who received the intervention at each centre) was 50-86%. Mean number of visits to the emergency department or admissions to hospital per patient was 0.91 (standard deviation 0.28) in the intervention arm and 0.94 (0.40) in the control arm (P=0.94); 47% (1014 of 2158 patients) had at least one visit to the emergency department or a hospital admission during chemotherapy. Among 580 participants who completed the patient reported outcome questionnaires, at least one grade 3 toxicity was reported by 48% (134 of 278 patients) in the intervention arm and by 58% (163 of 283) in the control arm. No differences in self-efficacy, anxiety, or depression were found. Compared with baseline, the functional assessment of cancer therapy trial outcome index decreased by 6.1 and 9.0 points in the intervention and control participants, respectively. CONCLUSIONS: Proactive, telephone based management of toxicities during chemotherapy did not result in fewer visits to the emergency department or hospital admissions. With the rapid rise in remote care because of the covid-19 pandemic, identifying scalable strategies for remote management of patients during cancer treatment is particularly relevant. TRIAL REGISTRATION: ClinicalTrials.gov NCT02485678. |
format | Online Article Text |
id | pubmed-8652580 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BMJ Publishing Group Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-86525802021-12-22 Remote, proactive, telephone based management of toxicity in outpatients during adjuvant or neoadjuvant chemotherapy for early stage breast cancer: pragmatic, cluster randomised trial Krzyzanowska, Monika K Julian, Jim A Gu, Chu-Shu Powis, Melanie Li, Qing Enright, Katherine Howell, Doris Earle, Craig C Gandhi, Sonal Rask, Sara Brezden-Masley, Christine Dent, Susan Hajra, Leena Freeman, Orit Spadafora, Silvana Hamm, Caroline Califaretti, Nadia Trudeau, Maureen Levine, Mark N Amir, Eitan Bordeleau, Louise Chiarotto, James A Elser, Christine Husain, Juhi Laferriere, Nicole Rahim, Yasmin Robinson, Andrew G Vandenberg, Ted Grunfeld, Eva BMJ Research OBJECTIVE: To evaluate the effectiveness of remote proactive management of toxicities during chemotherapy for early stage breast cancer. DESIGN: Pragmatic, cluster randomised trial. SETTING: 20 cancer centres in Ontario, Canada, allocated by covariate constrained randomisation to remote management of toxicities or routine care. PARTICIPANTS: All patients starting adjuvant or neoadjuvant chemotherapy for early stage breast cancer at each centre. 25 patients from each centre completed patient reported outcome questionnaires. INTERVENTIONS: Proactive, standardised, nurse led telephone management of common toxicities at two time points after each chemotherapy cycle. MAIN OUTCOME MEASURES: The primary outcome, cluster level mean number of visits to the emergency department or admissions to hospital per patient during the whole course of chemotherapy treatment, was evaluated with routinely available administrative healthcare data. Secondary patient reported outcomes included toxicity, self-efficacy, and quality of life. RESULTS: Baseline characteristics of participants were similar in the intervention (n=944) and control arms (n=1214); 22% were older than 65 years. Penetration (that is, the percentage of patients who received the intervention at each centre) was 50-86%. Mean number of visits to the emergency department or admissions to hospital per patient was 0.91 (standard deviation 0.28) in the intervention arm and 0.94 (0.40) in the control arm (P=0.94); 47% (1014 of 2158 patients) had at least one visit to the emergency department or a hospital admission during chemotherapy. Among 580 participants who completed the patient reported outcome questionnaires, at least one grade 3 toxicity was reported by 48% (134 of 278 patients) in the intervention arm and by 58% (163 of 283) in the control arm. No differences in self-efficacy, anxiety, or depression were found. Compared with baseline, the functional assessment of cancer therapy trial outcome index decreased by 6.1 and 9.0 points in the intervention and control participants, respectively. CONCLUSIONS: Proactive, telephone based management of toxicities during chemotherapy did not result in fewer visits to the emergency department or hospital admissions. With the rapid rise in remote care because of the covid-19 pandemic, identifying scalable strategies for remote management of patients during cancer treatment is particularly relevant. TRIAL REGISTRATION: ClinicalTrials.gov NCT02485678. BMJ Publishing Group Ltd. 2021-12-08 /pmc/articles/PMC8652580/ /pubmed/34880055 http://dx.doi.org/10.1136/bmj-2021-066588 Text en © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Research Krzyzanowska, Monika K Julian, Jim A Gu, Chu-Shu Powis, Melanie Li, Qing Enright, Katherine Howell, Doris Earle, Craig C Gandhi, Sonal Rask, Sara Brezden-Masley, Christine Dent, Susan Hajra, Leena Freeman, Orit Spadafora, Silvana Hamm, Caroline Califaretti, Nadia Trudeau, Maureen Levine, Mark N Amir, Eitan Bordeleau, Louise Chiarotto, James A Elser, Christine Husain, Juhi Laferriere, Nicole Rahim, Yasmin Robinson, Andrew G Vandenberg, Ted Grunfeld, Eva Remote, proactive, telephone based management of toxicity in outpatients during adjuvant or neoadjuvant chemotherapy for early stage breast cancer: pragmatic, cluster randomised trial |
title | Remote, proactive, telephone based management of toxicity in outpatients during adjuvant or neoadjuvant chemotherapy for early stage breast cancer: pragmatic, cluster randomised trial |
title_full | Remote, proactive, telephone based management of toxicity in outpatients during adjuvant or neoadjuvant chemotherapy for early stage breast cancer: pragmatic, cluster randomised trial |
title_fullStr | Remote, proactive, telephone based management of toxicity in outpatients during adjuvant or neoadjuvant chemotherapy for early stage breast cancer: pragmatic, cluster randomised trial |
title_full_unstemmed | Remote, proactive, telephone based management of toxicity in outpatients during adjuvant or neoadjuvant chemotherapy for early stage breast cancer: pragmatic, cluster randomised trial |
title_short | Remote, proactive, telephone based management of toxicity in outpatients during adjuvant or neoadjuvant chemotherapy for early stage breast cancer: pragmatic, cluster randomised trial |
title_sort | remote, proactive, telephone based management of toxicity in outpatients during adjuvant or neoadjuvant chemotherapy for early stage breast cancer: pragmatic, cluster randomised trial |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8652580/ https://www.ncbi.nlm.nih.gov/pubmed/34880055 http://dx.doi.org/10.1136/bmj-2021-066588 |
work_keys_str_mv | AT krzyzanowskamonikak remoteproactivetelephonebasedmanagementoftoxicityinoutpatientsduringadjuvantorneoadjuvantchemotherapyforearlystagebreastcancerpragmaticclusterrandomisedtrial AT julianjima remoteproactivetelephonebasedmanagementoftoxicityinoutpatientsduringadjuvantorneoadjuvantchemotherapyforearlystagebreastcancerpragmaticclusterrandomisedtrial AT guchushu remoteproactivetelephonebasedmanagementoftoxicityinoutpatientsduringadjuvantorneoadjuvantchemotherapyforearlystagebreastcancerpragmaticclusterrandomisedtrial AT powismelanie remoteproactivetelephonebasedmanagementoftoxicityinoutpatientsduringadjuvantorneoadjuvantchemotherapyforearlystagebreastcancerpragmaticclusterrandomisedtrial AT liqing remoteproactivetelephonebasedmanagementoftoxicityinoutpatientsduringadjuvantorneoadjuvantchemotherapyforearlystagebreastcancerpragmaticclusterrandomisedtrial AT enrightkatherine remoteproactivetelephonebasedmanagementoftoxicityinoutpatientsduringadjuvantorneoadjuvantchemotherapyforearlystagebreastcancerpragmaticclusterrandomisedtrial AT howelldoris remoteproactivetelephonebasedmanagementoftoxicityinoutpatientsduringadjuvantorneoadjuvantchemotherapyforearlystagebreastcancerpragmaticclusterrandomisedtrial AT earlecraigc remoteproactivetelephonebasedmanagementoftoxicityinoutpatientsduringadjuvantorneoadjuvantchemotherapyforearlystagebreastcancerpragmaticclusterrandomisedtrial AT gandhisonal remoteproactivetelephonebasedmanagementoftoxicityinoutpatientsduringadjuvantorneoadjuvantchemotherapyforearlystagebreastcancerpragmaticclusterrandomisedtrial AT rasksara remoteproactivetelephonebasedmanagementoftoxicityinoutpatientsduringadjuvantorneoadjuvantchemotherapyforearlystagebreastcancerpragmaticclusterrandomisedtrial AT brezdenmasleychristine remoteproactivetelephonebasedmanagementoftoxicityinoutpatientsduringadjuvantorneoadjuvantchemotherapyforearlystagebreastcancerpragmaticclusterrandomisedtrial AT dentsusan remoteproactivetelephonebasedmanagementoftoxicityinoutpatientsduringadjuvantorneoadjuvantchemotherapyforearlystagebreastcancerpragmaticclusterrandomisedtrial AT hajraleena remoteproactivetelephonebasedmanagementoftoxicityinoutpatientsduringadjuvantorneoadjuvantchemotherapyforearlystagebreastcancerpragmaticclusterrandomisedtrial AT freemanorit remoteproactivetelephonebasedmanagementoftoxicityinoutpatientsduringadjuvantorneoadjuvantchemotherapyforearlystagebreastcancerpragmaticclusterrandomisedtrial AT spadaforasilvana remoteproactivetelephonebasedmanagementoftoxicityinoutpatientsduringadjuvantorneoadjuvantchemotherapyforearlystagebreastcancerpragmaticclusterrandomisedtrial AT hammcaroline remoteproactivetelephonebasedmanagementoftoxicityinoutpatientsduringadjuvantorneoadjuvantchemotherapyforearlystagebreastcancerpragmaticclusterrandomisedtrial AT califarettinadia remoteproactivetelephonebasedmanagementoftoxicityinoutpatientsduringadjuvantorneoadjuvantchemotherapyforearlystagebreastcancerpragmaticclusterrandomisedtrial AT trudeaumaureen remoteproactivetelephonebasedmanagementoftoxicityinoutpatientsduringadjuvantorneoadjuvantchemotherapyforearlystagebreastcancerpragmaticclusterrandomisedtrial AT levinemarkn remoteproactivetelephonebasedmanagementoftoxicityinoutpatientsduringadjuvantorneoadjuvantchemotherapyforearlystagebreastcancerpragmaticclusterrandomisedtrial AT amireitan remoteproactivetelephonebasedmanagementoftoxicityinoutpatientsduringadjuvantorneoadjuvantchemotherapyforearlystagebreastcancerpragmaticclusterrandomisedtrial AT bordeleaulouise remoteproactivetelephonebasedmanagementoftoxicityinoutpatientsduringadjuvantorneoadjuvantchemotherapyforearlystagebreastcancerpragmaticclusterrandomisedtrial AT chiarottojamesa remoteproactivetelephonebasedmanagementoftoxicityinoutpatientsduringadjuvantorneoadjuvantchemotherapyforearlystagebreastcancerpragmaticclusterrandomisedtrial AT elserchristine remoteproactivetelephonebasedmanagementoftoxicityinoutpatientsduringadjuvantorneoadjuvantchemotherapyforearlystagebreastcancerpragmaticclusterrandomisedtrial AT husainjuhi remoteproactivetelephonebasedmanagementoftoxicityinoutpatientsduringadjuvantorneoadjuvantchemotherapyforearlystagebreastcancerpragmaticclusterrandomisedtrial AT laferrierenicole remoteproactivetelephonebasedmanagementoftoxicityinoutpatientsduringadjuvantorneoadjuvantchemotherapyforearlystagebreastcancerpragmaticclusterrandomisedtrial AT rahimyasmin remoteproactivetelephonebasedmanagementoftoxicityinoutpatientsduringadjuvantorneoadjuvantchemotherapyforearlystagebreastcancerpragmaticclusterrandomisedtrial AT robinsonandrewg remoteproactivetelephonebasedmanagementoftoxicityinoutpatientsduringadjuvantorneoadjuvantchemotherapyforearlystagebreastcancerpragmaticclusterrandomisedtrial AT vandenbergted remoteproactivetelephonebasedmanagementoftoxicityinoutpatientsduringadjuvantorneoadjuvantchemotherapyforearlystagebreastcancerpragmaticclusterrandomisedtrial AT grunfeldeva remoteproactivetelephonebasedmanagementoftoxicityinoutpatientsduringadjuvantorneoadjuvantchemotherapyforearlystagebreastcancerpragmaticclusterrandomisedtrial |